<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279615</url>
  </required_header>
  <id_info>
    <org_study_id>MIRTAM-2014OB</org_study_id>
    <nct_id>NCT02279615</nct_id>
  </id_info>
  <brief_title>Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.</brief_title>
  <official_title>EFFICACY AND SAFETY OF COMBINATION THERAPY WITH β3-ADRENOCEPTOR AGONIST (MIRABEGRON) AND α-ADRENOCEPTOR ANTAGONIST (TAMSULOSIN) FOR TREATMENT OF OVERACTIVE BLADDER IN MALE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Joseph's Healthcare Hamilton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of combination therapy
      involving β3-adrenoceptor agonist, mirabegron, and α-blockers for the treatment of OAB
      symptoms in male patients with BPH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mirabegron (MyrbetriqTM, Astellas Pharma Inc.) is a drug that is approved by the FDA for the
      treatment of overactive bladder (OAB) with symptoms of urinary frequency, urgency and urgency
      incontinence. Multiple studies have shown that this drug also has the potential to improve
      patient tolerability, compliance and subsequent patient quality of life without inducing
      unfavourable adverse events commonly associated with antimuscarinic medications. These
      adverse events include, but are not limited to, dry mouth, constipation, confusion, and acute
      urinary retention (AUR).

      Studies now have shown that mirabegron may also provide an effective treatment option for OAB
      in men with benign prostatic hyperplasia (BPH) without inducing the above mentioned adverse
      events. This study will look at the combination therapy of Mirabegron and Tamsulosin, versus
      Tamsulosin and placebo alone to prove that this treatment (Mirabegron and Tamsulosin) is
      effective for those men who suffer from both overactive bladder along with benign prostatic
      hyperplasia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>Treatment period: 4 weeks</time_frame>
    <description>Measured before and after combination therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life Score (QoLS)</measure>
    <time_frame>Treatment period: 4 weeks</time_frame>
    <description>Measured before and after combination therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overactive Bladder Symptom Score (OABSS)</measure>
    <time_frame>Treatment period: 4 weeks</time_frame>
    <description>Measured before and after combination therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Timeline: 4 weeks</time_frame>
    <description>Measured during treatment of combination therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Mirabegron + Tamsulosin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(Placebo + Tamsulosin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>50mg of mirabegron per day will be given.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Myrbetriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>0.4mg of flomax per day.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Flomax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients over the age of 50

          -  Clinical BPH on stable dose of alpha-blocker therapy for more than 1 month

          -  OAB symptoms (frequency, urgency, nocturia, urgency incontinence)

        Exclusion Criteria:

          -  Post-void residual (PVR) &gt; 200mL

          -  Active, culture-proven urinary tract infection

          -  Acute/chronic prostatitis

          -  Previous lower urinary tract malignancy (i.e. bladder, prostate malignancy)

          -  History of cystolithiasis

          -  Previous pelvic surgery (i.e. prostatectomy, cystectomy, recent pelvic/endourologic
             instrumentation including cystoscopy, nephroscopy, ureteral stent insertion,
             Transrectal Ultrasound (TRUS) biopsy)

          -  Previous pelvic radiation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Kapoor, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taehyoung Lee, MD, PGY4</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>36188</phone_ext>
    <email>taehyoung.lee@medportal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Camilla Tajzler, BA, CCRA</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>35876</phone_ext>
    <email>tajzlec@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton - McMaster Institute of Urology</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Joseph's Healthcare Hamilton</investigator_affiliation>
    <investigator_full_name>Anil Kapoor</investigator_full_name>
    <investigator_title>MD, FRCSC</investigator_title>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>Benign Prostatic Hyperplasia</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>β3-Adrenoceptor Agonist</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Myrbetriq</keyword>
  <keyword>α-Adrenoceptor Antagonist</keyword>
  <keyword>Tamsulosin</keyword>
  <keyword>Flomax</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

